Ken Griffin Viatris Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.32 - $12.13 $250,776 - $294,759	24,300 Added 10.97%	245,800 $2.85 Million
Q2 2024 Aug 14, 2024	SELL	$10.05 - $12.02 $2.05 Million - $2.45 Million	-203,700 Reduced 47.91%	221,500 $2.35 Million
Q1 2024 May 15, 2024	BUY	$11.27 - $13.53 $1.71 Million - $2.05 Million	151,800 Added 55.52%	425,200 $5.08 Million
Q4 2023 Feb 14, 2024	BUY	$8.77 - $10.85 $107,871 - $133,455	12,300 Added 4.71%	273,400 $2.96 Million
Q3 2023 Nov 14, 2023	BUY	$9.59 - $11.35 $469,910 - $556,150	49,000 Added 23.1%	261,100 $2.57 Million
Q2 2023 Aug 14, 2023	SELL	$9.02 - $10.29 $45,100 - $51,449	-5,000 Reduced 2.3%	212,100 $2.12 Million
Q1 2023 May 15, 2023	SELL	$9.2 - $12.26 $823,399 - $1.1 Million	-89,500 Reduced 29.19%	217,100 $2.09 Million
Q4 2022 Feb 14, 2023	SELL	$8.72 - $11.56 $81,619 - $108,201	-9,360 Reduced 2.96%	306,600 $3.41 Million
Q3 2022 Nov 14, 2022	SELL	$8.48 - $11.13 $183,168 - $240,408	-21,600 Reduced 6.4%	315,960 $2.69 Million

1,102

933M

2.71M

2.4M

Ticker VTRS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,212,669,952
Market Cap $15.2B
Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.